Two of 7 patients with acromegaly and one of 7 normal subjects exhibited a paradoxical rise in growth hormone (GH) to human corticotropin-releasing hormone (CRH) when pretreated with metoclopramide, although CRH alone did not induce an increase in GH. In one of these two patients with acromegaly, the GH increase to metoclopramide alone also reached the criteria of a paradoxical response.
demonstrated that, in addition to TRH and LHRH, ovine corticotropin-releasing hormone (CRH) elicited an increase in serum GH in patients with acromegaly. They recognized these paradoxical responses in two of six patients with acromegaly and concluded that the receptors of the GH-producing cells in acromegalic patients are dedifferentiated. It has been shown that GH levels are not influenced by the administrations of CRH to normal subjects, whether ovine CRH (Grossman et al., 1982; Orth et al., 1983; Hermus et al., 1984) or human CRH (Schurmeyer et al., 1984) . However, paradoxical GH responses to oCRH have been reported in patients with primary affective disorders (Gold et al., 1983) , and these responses were observed to be abolished by alpha-adrenergic blockade in subhuman primates in the same study. We recently demonstrated that metoclopramide acts additively with hCRH to stimulate ACTH secretion in normal men through a dopamine antagonist-mediated mechanism and that a normal cortisol response to metoclopramide-CRH was absent in acromegalic patients (Nishida et al., 1987) . In the present study, the effects of metoclopramide on hCRHinduced GH release were studied in acromegalic patients and normal subjects to examine whether a centrally occurring antidopaminergic change modulates paradoxical GH responses to CRH. Serum GH was determined by RIA (RIA kit, Dainabot, Tokyo, Japan). The assay sensitivity was 0.5ng/mL and the mean intra-and interassay coefficients of variation were 3.9% and 4.1%, respectively.
The mean recovery was 94.7%.
Results

Acromegalic patients
As shown in Table 1 and Fig. 1 ., case 1 showed, before surgery, a paradoxical rise in GH to CRH (more than 50% above the baseline in at least 2 samples within 30 min (Pieters et al., 1982) ) when pretreated with metoclopramide. CRH alone did not induce an increase in GH. The GH increase to metoclopramide alone did not reach the criteria of a paradoxical response. The re- Data is listed in details in Table 1 . sponses of GH to CRH and/or metoclopramide 2 months after surgery, when the basal GH levels were still elevated above normal levels, were similar to those before surgery.
Case 2 also showed, before surgery, a paradoxical rise in GH to CRH when pretreated with metoclopramide.
CRH alone did not induce a GH increase. However, the GH increase to metoclopramide alone reached the criteria of a paradoxical response, and the increase as in the metoclopramide-CRH test was not seen in the pretreatment test with L-dopa. The responses of GH to CRH and/or metoclopramide 2 months after surgery, when the basal GH levels entered the normal range, were similar to those before surgery.
Case 3, with high basal GH levels persisting 5 months after surgery, showed a GH increase to metoclopramide-CRH, but not to CRH alone. Case 4 showed an increase in GH to CRH and metoclopramide-CRH (only at 15min) before surgery, but not 18 months after surgery, although a normal GH level
was not yet achieved. Cases 5 to 7 with normal GH 2 years or more after surgery showed no increase in GH to either CRH or metoclopramide-CRH.
Normal subjects
As shown in Table 2 and Fig. 2 , subject 1 showed a paradoxical rise in GH to CRH when pretreated with metoclopramide. Administrations of CRH or metoclopramide alone showed late effects (60min or later) on the GH increase. Pretreament with Ldopa induced an increase in the basal GH level and abolished the metoclopramide-CRH-induced GH increase. Subjects 2 to 7 showed no increases in GH to either CRH or metoclopramide-CRH.
Discussion
A rise in GH levels in response to CRH was considered a paradoxical response when the GH levels increased over 50% above the basal level in at least two samples and within 30min (Pieters et al., 1982) . Pieters et al.(1984) reported a paradoxical GH response to ovine CRH in 2 of 6 patients with acromegaly, although in the present study human CRH alone did not induce a paradoxical GH response in either 7 acromegalic patients or 7 normal subjects. The reason for the difference between the two studies is unclear. Lytras et al.(1984) and Tanaka et al.(1984) also reported that acromegalic patients did not show a GH response to oCRH. In vitro studies, however, revealed that some pituitary adenoma cells of acromegalics responded to oCRH to secrete GH. Ishibashi et al.(1984) demonstrated that in 3 outof 7 experiments using different pituitary adenoma cells in a culture, oCRH caused a significant increase in GH release and explained the results by a possible alteration in cellular membrane receptors of adenoma cells. In the present study, we used synthetic hCRH, while syn- is apparent that metoclopramide has an effect on GH secretion from the pituitary of acromegalic patients. However, previous studies and the present study indicate that circulating GH does not respond to metoclopramide in normal adults (Sowers et al., 1976; Cohen et al., 1979; Andersen and Tabor, 1982) , although it did produce an increase in GH in children, adolescents and normal women (Cohen et al., 1979; Hagen et al., 1984; Massara et al ., 1985) .
The following points suggest that the GH response to metoclopramide and the metoclopramide-provoked paradoxical GH response to CRH in patients with acromegaly are due mainly to GH secretion from the nonadenomatous cells of the pituitary:
1) The patterns of response of GH to the stimuli were similar pre-and postoperatively in case 1 (high postoperative GH level) and case 2 (normal postoperative GH level). 2) Case 4 showed no GH response to metoclopramide 18 months after surgery, at which time a normal GH level had not yet been achieved, while case 3 showed a GH rise to metoclopramide 5 months after surgery, at which time the GH level remained high. 3) Cases 5 to 7 exhibited no GH responses to metoclopramide 2 years or more after surgery . 4) Metoclopramide provoked a paradoxical GH rise to CRH in one normal subject . Case 4 exhibited a GH response to metoclopramide which differed from that of the rest of the cases. The large increase in GH to metoclopramide-CRH or CRH alone at 15 min during the preoperative test was not observed in the postoperative period when the GH level had decreased remarkably . Therefore, the early (15 min) increase in GH might be due to secretion mainly from the adenoma cells.
In patients with acromegaly , metoclopramide may stimulate GH secretion from the nonadenomatous cells by its dopamine antagonist properties or by an unknown effect on disordered catecholamine neurons which may exist in the hypothalamus and pituitary of patients with acromegaly (Van Loon, 1979; Nishida et al., 1987) . These effects may simultaneously provoke a paradoxical GH rise to CRH in some patients with acromegaly. It is suggested that the hypersensitivity of nonadenomatous cells to metoclopramide which results in GH secretion may be suppressed along with the resumption of the physiological GH secretion pattern about 18 months or more postoperatively.
